NASDAQ:AZN - AstraZeneca Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $89.50
  • Forecasted Upside: 78.71 %
  • Number of Analysts: 15
  • Breakdown:
  • 2 Sell Ratings
  • 2 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$50.08
▲ +0.89 (1.81%)
1 month | 3 months | 12 months
Get New AstraZeneca Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AZN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AZN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$89.50
▲ +78.71% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $89.50, with a high forecast of $175.00 and a low forecast of $60.00. The average price target represents a 78.71% upside from the last price of $50.08.
Buy
The current consensus among 15 contributing investment analysts is to buy stock in AstraZeneca. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 2 sell ratings
10/21/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings
1/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
4/18/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 2 sell ratings
7/17/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/15/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 2 sell ratings
1/13/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 2 sell ratings
3/14/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 2 sell ratings
4/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2021ArgusDowngradeBuy ➝ HoldMedium
i
3/23/2021Societe GeneraleReiterated RatingBuyLow
i
3/22/2021Jefferies Financial GroupUpgradeHold ➝ BuyN/A
i
3/18/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
3/16/2021Jefferies Financial GroupUpgradeHold ➝ BuyLow
i
3/9/2021Berenberg BankReiterated RatingBuyLow
i
3/8/2021BarclaysReiterated RatingOverweightMedium
i
3/8/2021SVB LeerinkLower Price TargetOutperform$64.00 ➝ $63.00N/A
i
3/3/2021UBS GroupUpgradeNeutral ➝ BuyMedium
i
3/2/2021SVB LeerinkLower Price TargetOutperform$64.00 ➝ $63.00Low
i
2/25/2021UBS GroupUpgradeNeutral ➝ BuyMedium
i
1/22/2021BarclaysReiterated RatingOverweightLow
i
1/15/2021Berenberg BankReiterated RatingBuyLow
i
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
i
12/30/2020AlphaValueUpgradeReduceN/A
i
12/14/2020UBS GroupReiterated RatingPositiveHigh
i
12/13/2020Piper SandlerLower Price TargetOverweight$179.00 ➝ $175.00High
i
12/7/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
i
11/30/2020UBS GroupUpgradeSell ➝ NeutralMedium
i
11/23/2020Morgan StanleyReiterated RatingEqual WeightMedium
i
11/11/2020HSBCUpgradeReduce ➝ HoldLow
i
9/29/2020Berenberg BankInitiated CoverageBuyLow
i
9/23/2020Oddo BhfUpgradeReduce ➝ BuyLow
i
7/29/2020BarclaysReiterated RatingOverweightLow
i
6/24/2020Oddo BhfDowngradeBuy ➝ ReduceLow
i
6/10/2020CowenBoost Price Target$55.00 ➝ $60.00Low
i
Rating by Steve Scala at Cowen Inc
6/4/2020UBS GroupReiterated RatingSellLow
i
5/29/2020GuggenheimReiterated RatingBuyMedium
i
5/29/2020SVB LeerinkBoost Price TargetOutperform$60.00 ➝ $65.00Low
i
5/6/2020Morgan StanleyReiterated RatingEqual WeightLow
i
5/6/2020ArgusBoost Price TargetBuy$54.00 ➝ $60.00Low
i
5/1/2020GuggenheimReiterated RatingBuyLow
i
4/27/2020BarclaysReiterated RatingOverweightLow
i
4/23/2020FIG PartnersInitiated CoverageReduceLow
i
4/15/2020Morgan StanleyReiterated RatingEqual WeightLow
i
2/28/2020CowenReiterated RatingBuy$55.00High
i
Rating by Steve Scala at Cowen Inc
12/2/2019CowenReiterated RatingOutperform$48.00 ➝ $55.00Low
i
11/11/2019CowenReiterated RatingBuy$48.00Low
i
10/24/2019Liberum CapitalReiterated RatingHold ➝ HoldLow
i
9/3/2019DZ BankDowngradeHold ➝ SellLow
i
8/14/2019ArgusBoost Price TargetBuy$50.00Medium
i
4/29/2019Pareto SecuritiesUpgradeSell ➝ HoldLow
i
4/2/2019UBS GroupDowngradeNeutral ➝ Sell$40.73Medium
i
Rating by Jack Scannell at UBS Group AG
4/1/2019CowenUpgradeMarket Perform ➝ Outperform$42.00 ➝ $48.00Low
i
3/19/2019Main First BankReiterated RatingBuyLow
i
Rating by Michael Leacock at Main First Bank AG
2/28/2019HSBCReiterated RatingSellMedium
i
Rating by Steve McGarry at HSBC Holdings plc
2/26/2019Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
Rating by Richard Parkes at Deutsche Bank Aktiengesellschaft
2/26/2019The Goldman Sachs GroupReiterated RatingSellLow
i
Rating by Keyur Parekh at The Goldman Sachs Group, Inc.
2/5/2019Exane BNP ParibasInitiated CoverageOutperformLow
i
2/5/2019BNP ParibasInitiated CoverageOutperform ➝ OutperformLow
i
1/15/2019BMO Capital MarketsReiterated RatingBuy$48.00Medium
i
12/14/2018Bank of AmericaReiterated RatingBuyLow
i
Rating by Sachin Jain at Bank of America Co.
12/13/2018SunTrust BanksInitiated CoverageBuy$48.00Low
i
12/11/2018Jefferies Financial GroupReiterated RatingHold ➝ Hold$42.00Medium
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
12/9/2018Credit Suisse GroupReiterated RatingBuyLow
i
11/28/2018HSBCReiterated RatingSellLow
i
Rating by Steve McGarry at HSBC Holdings plc
11/19/2018UBS GroupReiterated RatingHoldLow
i
Rating by Jack Scannell at UBS Group AG
11/19/2018BMO Capital MarketsReiterated RatingPositive ➝ Outperform$48.00Medium
i
11/19/2018InvestecDowngradeBuy ➝ HoldMedium
i
11/16/2018The Goldman Sachs GroupReiterated RatingSellLow
i
11/12/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
Rating by Richard Parkes at Deutsche Bank Aktiengesellschaft
11/12/2018HSBCReiterated RatingSellMedium
i
10/23/2018Wolfe ResearchInitiated CoverageOutperformLow
i
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyLow
i
8/16/2018Jefferies Financial GroupDowngradeBuy ➝ HoldMedium
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
6/12/2018MorningstarReiterated RatingHoldLow
i
Rating by Damien Conover at Morningstar, Inc.
5/25/2018BMO Capital MarketsReiterated RatingBuy$41.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
3/22/2018BMO Capital MarketsSet Price TargetBuy$40.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
3/19/2018Jefferies Financial GroupUpgradeHold ➝ Buy$28.43 ➝ $36.70Low
i
2/20/2018BMO Capital MarketsSet Price TargetBuy$40.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
2/6/2018SVB LeerinkBoost Price TargetMarket Perform ➝ Market Perform$36.00 ➝ $38.00Medium
i
2/5/2018Sanford C. BernsteinBoost Price TargetOutperform$40.00 ➝ $42.00High
i
2/4/2018BMO Capital MarketsReiterated RatingBuyHigh
i
Rating by Alex Arfaei at BMO Capital Markets
1/26/2018BMO Capital MarketsReiterated RatingBuy$38.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
1/18/2018SVB LeerinkReiterated RatingMkt Perform ➝ Market Perform$33.00 ➝ $36.00Low
i
Rating by S. Fernandez at SVB Leerink LLC
1/10/2018BMO Capital MarketsSet Price TargetBuy$38.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
12/29/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
i
Rating by James Gordon at JPMorgan Chase & Co.
11/15/2017BMO Capital MarketsSet Price TargetBuy$38.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
11/7/2017BMO Capital MarketsReiterated RatingBuy$38.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/31/2017BMO Capital MarketsSet Price TargetBuy$38.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/23/2017SVB LeerinkBoost Price TargetMarket Perform$31.00 ➝ $34.00N/A
i
Rating by S. Fernandez at SVB Leerink LLC
10/18/2017CitigroupUpgradeBuyN/A
i
Rating by Andrew Baum at Citigroup Inc.
10/17/2017CowenReiterated RatingHold$37.00N/A
i
10/16/2017Credit Suisse GroupUpgradeNeutral ➝ OutperformN/A
i
Rating by Rebekah Harper at Credit Suisse Group AG
9/25/2017BNP ParibasUpgradeNeutral ➝ OutperformMedium
i
9/22/2017Sanford C. BernsteinReiterated RatingMkt Perform ➝ BuyLow
i
9/22/2017Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$30.00 ➝ $39.00Medium
i
9/14/2017Liberum CapitalDowngradeBuy ➝ HoldLow
i
9/6/2017BMO Capital MarketsInitiated CoverageOutperform$38.00High
i
9/6/2017NatixisUpgradeNeutral ➝ BuyLow
i
9/1/2017ArgusReiterated RatingBuy$35.00Low
i
8/9/2017InvestecUpgradeHold ➝ BuyLow
i
8/9/2017Piper Jaffray CompaniesReiterated RatingBuyLow
i
Rating by Richard Purkiss at Piper Jaffray Companies
8/1/2017Pareto SecuritiesUpgradeSell ➝ HoldLow
i
7/28/2017Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
i
7/28/2017CowenReiterated RatingHold$34.00High
i
7/27/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$36.00 ➝ $31.00High
i
Rating by S. Fernandez at SVB Leerink LLC
7/13/2017The Goldman Sachs GroupReiterated RatingSellHigh
i
7/13/2017BarclaysReiterated RatingOverweightHigh
i
Rating by Emmanuel Papadakis at Barclays PLC
7/3/2017BarclaysReiterated RatingOverweightLow
i
Rating by Emmanuel Papadakis at Barclays PLC
5/17/2017SVB LeerinkReiterated RatingOutperform$33.00 ➝ $36.00Low
i
Rating by S. Fernandez at SVB Leerink LLC
5/12/2017Credit Suisse GroupUpgradeUnderperform ➝ NeutralHigh
i
4/10/2017Jefferies Financial GroupReiterated RatingBuy ➝ HoldLow
i
4/5/2017UBS GroupDowngradeBuy ➝ Neutral$35.44 ➝ $25.55N/A
i
3/20/2017SVB LeerinkReiterated RatingOutperformLow
i
Rating by S. Fernandez at SVB Leerink LLC
3/9/2017Liberum CapitalInitiated CoverageBuy ➝ BuyLow
i
3/7/2017BarclaysInitiated CoverageOverweightN/A
i
3/6/2017CowenReiterated RatingMarket PerformN/A
i
2/21/2017Berenberg BankReiterated RatingBuyN/A
i
1/21/2017SVB LeerinkReiterated RatingOutperformN/A
i
Rating by S. Fernandez at SVB Leerink LLC
12/13/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
12/9/2016SVB LeerinkUpgradeMarket Perform ➝ Outperform$34.00N/A
i
Rating by S. Fernandez at SVB Leerink LLC
11/25/2016Liberum CapitalUpgradeHold ➝ BuyN/A
i
11/11/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
11/11/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
11/11/2016Beaufort SecuritiesReiterated RatingHoldN/A
i
11/10/2016SVB LeerinkReiterated RatingMarket PerformN/A
i
Rating by S. Fernandez at SVB Leerink LLC
11/10/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
11/10/2016Bank of AmericaReiterated RatingBuy$41.37N/A
i
Rating by Sachin Jain at Bank of America Co.
11/10/2016Shore CapitalReiterated RatingHoldN/A
i
11/7/2016CitigroupReiterated RatingBuyN/A
i
11/2/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
10/28/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
10/28/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
10/10/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
10/9/2016SVB LeerinkReiterated RatingHold$35.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
10/8/2016Shore CapitalReiterated RatingHoldN/A
i
10/5/2016The Goldman Sachs GroupReiterated RatingSellN/A
i
Rating by Keyur Parekh at The Goldman Sachs Group, Inc.
10/4/2016Bank of AmericaSet Price TargetBuy$41.00N/A
i
Rating by Sachin Jain at Bank of America Co.
10/4/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
9/28/2016Shore CapitalReiterated RatingHoldN/A
i
9/28/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
9/23/2016CitigroupReiterated RatingBuyN/A
i
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/A
i
9/13/2016BNP ParibasDowngradeOutperform ➝ NeutralN/A
i
9/12/2016Jefferies Financial GroupUpgradeHold ➝ BuyN/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
9/11/2016Berenberg BankReiterated RatingBuyN/A
i
9/8/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
9/8/2016Bank of AmericaSet Price TargetBuy$41.40N/A
i
Rating by Sachin Jain at Bank of America Co.
9/3/2016Shore CapitalReiterated RatingHoldN/A
i
8/29/2016ArgusUpgradeHold ➝ Buy$38.00N/A
i
Rating by Stephen Biggar at Argus
8/26/2016Beaufort SecuritiesReiterated RatingHoldN/A
i
8/11/2016Beaufort SecuritiesReiterated RatingHoldN/A
i
8/10/2016Shore CapitalReiterated RatingHoldN/A
i
8/10/2016CitigroupReiterated RatingBuyN/A
i
8/8/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
8/8/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
7/31/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
7/28/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
7/27/2016Shore CapitalReiterated RatingHoldN/A
i
7/27/2016CitigroupReiterated RatingBuyN/A
i
7/20/2016Shore CapitalReiterated RatingHoldN/A
i
7/19/2016Beaufort SecuritiesReiterated RatingHoldN/A
i
7/18/2016Bank of AmericaReiterated RatingBuy$36.65N/A
i
Rating by Sachin Jain at Bank of America Co.
7/12/2016ArgusInitiated CoverageHoldN/A
i
6/27/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
6/25/2016CitigroupReiterated RatingBuyN/A
i
6/16/2016SVB LeerinkReiterated RatingHold$34.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
6/14/2016Shore CapitalReiterated RatingHoldN/A
i
6/7/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
6/6/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
5/31/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
5/31/2016Beaufort SecuritiesReiterated RatingHoldN/A
i
5/27/2016The Goldman Sachs GroupReiterated RatingSellN/A
i
Rating by Keyur Parekh at The Goldman Sachs Group, Inc.
5/25/2016CitigroupReiterated RatingBuyN/A
i
5/23/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
5/19/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Sachin Jain at Bank of America Co.
5/18/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
5/17/2016Shore CapitalReiterated RatingHoldN/A
i
5/16/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
5/3/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
5/3/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Sachin Jain at Bank of America Co.
5/2/2016SVB LeerinkLower Price TargetMarket Perform$38.00 ➝ $34.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
4/21/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
4/20/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
4/18/2016UBS GroupReiterated RatingBuyN/A
i
4/17/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
(Data available from 4/14/2016 forward)
AstraZeneca logo
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; and AliveCor, Inc. to develop non-invasive potassium monitoring solutions. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $50.08
$49.86
$50.19

50 Day Range

MA: $49.22
$47.16
$51.20

52 Week Range

Now: $50.08
$46.48
$64.94

Volume

234,498 shs

Average Volume

10,844,784 shs

Market Capitalization

$131.44 billion

P/E Ratio

52.17

Dividend Yield

3.72%

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of AstraZeneca?

The following equities research analysts have issued reports on AstraZeneca in the last year: AlphaValue, Argus, Barclays PLC, Berenberg Bank, Cowen Inc, Deutsche Bank Aktiengesellschaft, FIG Partners, Guggenheim, HSBC Holdings plc, Jefferies Financial Group Inc., Morgan Stanley, Oddo Bhf, Piper Sandler, Societe Generale, SVB Leerink LLC, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for AZN.

What is the current price target for AstraZeneca?

4 Wall Street analysts have set twelve-month price targets for AstraZeneca in the last year. Their average twelve-month price target is $89.50, suggesting a possible upside of 81.9%. Piper Sandler has the highest price target set, predicting AZN will reach $175.00 in the next twelve months. Argus has the lowest price target set, forecasting a price of $60.00 for AstraZeneca in the next year.
View the latest price targets for AZN.

What is the current consensus analyst rating for AstraZeneca?

AstraZeneca currently has 2 sell ratings, 2 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AZN will outperform the market and that investors should add to their positions of AstraZeneca.
View the latest ratings for AZN.

What other companies compete with AstraZeneca?

How do I contact AstraZeneca's investor relations team?

AstraZeneca's physical mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company's listed phone number is 44 20 3749 5000 and its investor relations email address is [email protected] The official website for AstraZeneca is www.astrazeneca.com.